A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN
Public ClinicalTrials.gov record NCT05856760. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicentered, Single-group Phase 2, Exploratory, Open-label Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in the Treatment of Adult Participants With Immunoglobulin A Nephropathy (IgAN)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This was a 28-week, open-label, multicenter, single-group Phase 2 exploratory study to determine the safety and effect of sparsentan in participants with IgAN who are at risk of disease progression to kidney failure despite being on both stable RAASi and SGLT2 inhibitor treatment for at least 12 weeks prior to study entry
Study identification
- NCT ID
- NCT05856760
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 48 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 19, 2023 (Actual)
- Primary completion
- Oct 14, 2024 (Actual)
- Completion
- Oct 25, 2024 (Actual)
- Last update posted
- Nov 20, 2025
2023 – 2024
United States locations
- U.S. sites
- 25
- U.S. states
- 16
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Travere Investigational Site | Birmingham | Alabama | 35233 | — |
| Travere Investigational Site | Chula Vista | California | 91910 | — |
| Travere Investigational Site | Garden Grove | California | 92844 | — |
| Travere Investigational Site | Glendale | California | 91206 | — |
| Travere Investigational Site | Denver | Colorado | 80230 | — |
| Travere Investigational Site | Boise | Idaho | 83706 | — |
| Travere Investigational Site | Chubbuck | Idaho | 83202 | — |
| Travere Investigational Site | Idaho Falls | Idaho | 83404 | — |
| Travere Investigational Site | Chicago | Illinois | 60611 | — |
| Travere Investigational Site | Evergreen Park | Illinois | 60805 | — |
| Travere Investigational Site | Fort Wayne | Indiana | 46804 | — |
| Travere Investigational Site | Kansas City | Kansas | 66160 | — |
| Travere Investigational Site | Louisville | Kentucky | 40205 | — |
| Travere Investigational Site | Shreveport | Louisiana | 71101 | — |
| Travere Investigational Site | Albuquerque | New Mexico | 87109 | — |
| Travere Investigation Site | Clifton Park | New York | 12065 | — |
| Travere Investigational Site | Fresh Meadows | New York | 11365 | — |
| Travere Investigational Site | New York | New York | 10013 | — |
| Travere Investigational Site | Jacksonville | North Carolina | 28546 | — |
| Travere Investigational Site | New Bern | North Carolina | 28562 | — |
| Travere Investigational Site | Columbus | Ohio | 43210 | — |
| Travere Investigational Site | Philadelphia | Pennsylvania | 19104 | — |
| Travere Investigational Site | Columbia | South Carolina | 29203 | — |
| Travere Investigational Site | Dallas | Texas | 75230 | — |
| Travere Investigational Site | Dallas | Texas | 75246 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05856760, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 20, 2025 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05856760 live on ClinicalTrials.gov.